TY - JOUR
T1 - The Undiagnosed Diseases Network International
T2 - Five years and more!
AU - Taruscio, D.
AU - Baynam, G.
AU - Cederroth, H.
AU - Groft, S. C.
AU - Klee, E. W.
AU - Kosaki, K.
AU - Lasko, P.
AU - Melegh, B.
AU - Riess, O.
AU - Salvatore, M.
AU - Gahl, W. A.
N1 - Funding Information:
Although the success of the UDP and UDN in the United States was widely acknowledged, addressing URDs requires an international effort. Hence, the Undiagnosed Diseases Network International (UDNI) was established in 2014 to provide diagnoses and to foster research on novel diseases, their mechanisms, and their pathways [ 12 ]. Since then, undiagnosed diseases programs have sprung up in several countries. In Italy, the Ministry of Foreign Affairs funded “Undiagnosed Rare Diseases: A joint Italy-USA project” in 2016 [ 13 ]; the Telethon Undiagnosed Diseases Program and the Bambino Gesù Hospital initiative were also established. In Japan, the Agency for Medical Research and Development signed a memorandum of understanding with the U.S. Office of Science and Technology that included undiagnosed diseases and set aside $6 M towards its own UDP. The government of Western Australia sponsored an undiagnosed diseases conference in Perth and created an Undiagnosed Diseases Program. A group in Vienna secured funding from the Ludwig Boltzmann Gesellschaft to establish an Austrian UDP, and the European Union of Medical Specialists created a Multidisciplinary Joint Committee for Rare and Undiagnosed Diseases. To date, UDPs have been established in other countries as well, including Spain [ 14 ], Canada ( http://care4rare.ca/ ), Japan [ 15 ], Thailand [ 16 ], Sweden ( https://ki.se/en/mmk/undiagnosed-disease-program-udp ), Korea ( www.cdc.go.kr/menu.es?mid=a50401030000 ), Netherlands ( http://www.europlanproject.eu/Resources/docs/NATIONALPLANS_NETHERLAND_2012_Strategy.pdf ), Hungary ( http://www.eucerd.eu/?post_type=document&p=1484 ), China [ 17 ], Germany [ 18 ], France ( https://solidarites-sante.gouv.fr/IMG/pdf/pnmr3_-_en.pdf ), Switzerland ( https://www.grstiftung.ch/de/handlungsfelder/abgeschlossene-handlungsfelder/rare-diseases.html ), India ( http://www.icmrmetbionetindia.org/ ), and Israel ( https://eng.sheba.co.il/institute_for_rare_diseases ). Furthermore, several initiatives and congresses with specific sessions on undiagnosed diseases were held in different countries (e.g., South Africa, Mexico and Russia) to foster this important field.
Publisher Copyright:
© 2020
PY - 2020/4
Y1 - 2020/4
N2 - Undiagnosed rare diseases (URDs) account for a significant portion of the overall rare disease burden, depending upon the country. Hence, URDs represent an unmet medical need. A specific challenge posed by the ensemble of the URD patient cohort is the heterogeneity of its composition; the group, indeed, includes very rare, still unidentified conditions as well as clinical variants of recognized rare diseases. Exact disease recognition requires new approaches that cut across national and institutional boundaries, may need the implementation of methods new to diagnostics, and embrace clinical care and research. To address these issues, the Undiagnosed Diseases Network International (UDNI) was established in 2014, with the major aims of providing diagnoses to patients, implementing additional diagnostic tools, and fostering research on novel diseases, their mechanisms, and their pathways. The UDNI involves centres with internationally recognized expertise, and its scientific resources and know-how aim to fill the knowledge gaps that impede diagnosis, in particularly for ultra-rare diseases. Consequently, the UDNI fosters the translation of research into medical practice, aided by active patient involvement. The goals of the UDNI are to work collaboratively and at an international scale to: 1) provide diagnoses for individuals who have conditions that have eluded diagnosis by clinical experts; 2) gain insights into the etiology and pathogenesis of novel diseases; 3) contribute to standards of diagnosing unsolved patients; and 4) share the results of UDNI research in a timely manner and as broadly as possible.
AB - Undiagnosed rare diseases (URDs) account for a significant portion of the overall rare disease burden, depending upon the country. Hence, URDs represent an unmet medical need. A specific challenge posed by the ensemble of the URD patient cohort is the heterogeneity of its composition; the group, indeed, includes very rare, still unidentified conditions as well as clinical variants of recognized rare diseases. Exact disease recognition requires new approaches that cut across national and institutional boundaries, may need the implementation of methods new to diagnostics, and embrace clinical care and research. To address these issues, the Undiagnosed Diseases Network International (UDNI) was established in 2014, with the major aims of providing diagnoses to patients, implementing additional diagnostic tools, and fostering research on novel diseases, their mechanisms, and their pathways. The UDNI involves centres with internationally recognized expertise, and its scientific resources and know-how aim to fill the knowledge gaps that impede diagnosis, in particularly for ultra-rare diseases. Consequently, the UDNI fosters the translation of research into medical practice, aided by active patient involvement. The goals of the UDNI are to work collaboratively and at an international scale to: 1) provide diagnoses for individuals who have conditions that have eluded diagnosis by clinical experts; 2) gain insights into the etiology and pathogenesis of novel diseases; 3) contribute to standards of diagnosing unsolved patients; and 4) share the results of UDNI research in a timely manner and as broadly as possible.
KW - Diagnosis
KW - Global health
KW - Omics
KW - Ontology
KW - Rare diseases
KW - Undiagnosed
UR - http://www.scopus.com/inward/record.url?scp=85078856512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078856512&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2020.01.004
DO - 10.1016/j.ymgme.2020.01.004
M3 - Article
C2 - 32033911
AN - SCOPUS:85078856512
SN - 1096-7192
VL - 129
SP - 243
EP - 254
JO - Molecular Genetics and Metabolism
JF - Molecular Genetics and Metabolism
IS - 4
ER -